Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA
wet age-related macular degeneration
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews ONS-5010/LYTENAVA for wet age-related macular degeneration around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“a formal Type A meeting on March 2, 2026”